公开(公告)号：US20230053342A1

公开(公告)日：2023-02-23

申请号：US17773771

申请日：2020-11-04

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Houxian ZU ,  Xizhen SONG ,  Kai CHEN ,  Xiangyong LIU ,  Jie CHEN ,  Yajing BIAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D498/04 ,  C07D513/04 ,  A61P35/00

Abstract: An imidazolidinone compound represented by formula (I), or a stereoisomer thereof, a geometric isomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a synthesis method therefor and use thereof.

公开(公告)号：US20230022091A1

公开(公告)日：2023-01-26

申请号：US17898258

申请日：2022-08-29

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Yan XU ,  Xiaofeng XU ,  Jiabing WANG ,  Lieming DING

IPC: C07D519/00 ,  C07D471/06

Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.

公开(公告)号：US20220227796A1

公开(公告)日：2022-07-21

申请号：US17439324

申请日：2020-03-31

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Qichao SHEN ,  Mengqiang LIU ,  Haitong SHENG ,  Guolong DU ,  Jiabing WANG ,  Lieming DING

IPC: C07F9/6512 ,  C07F9/6561 ,  A61P35/00

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20210395256A1

公开(公告)日：2021-12-23

申请号：US17311105

申请日：2019-12-06

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Bang FU ,  Yinlong LI ,  Wei REN ,  Jie CHEN ,  Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07D487/04 ,  C07D519/00

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as Trk inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20210340142A1

公开(公告)日：2021-11-04

申请号：US17271410

申请日：2019-08-27

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Xiaofeng XU ,  Jiabing WANG ,  Lieming DING

IPC: C07D471/14 ,  A61P35/00

Abstract: A maleate, mesylate, benzene sulfonate, hydrochloride, phosphate, L-tartrate, L-malate, citrate, and fumarate of a compound represented by structural formula I, various crystal forms of each salt form, and a preparation method and application thereof.

公开(公告)号：US20210261546A1

公开(公告)日：2021-08-26

申请号：US17254097

申请日：2019-06-21

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Yiqian WANG ,  Chunhui ZHANG ,  Jiabing WANG ,  Lieming DING

IPC: C07D471/04 ,  A61P35/00

Abstract: The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.

公开(公告)号：US20240383974A1

公开(公告)日：2024-11-21

申请号：US18692312

申请日：2022-09-29

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Wenxin XU ,  Xuefei FANG ,  Deyu XU ,  Jieying XU ,  Lieming DING

IPC: C07K16/22 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

Abstract: Provided are a bispecific antibody and use thereof. The bispecific antibody provided can specifically bind to TGF-β, GARP, or GARP-TGF-β complex individually or simultaneously, and can also specifically bind to PD-L1. The bispecific antibody provided exhibits high affinity and specificity for the antigens, has a tumor-killing effect, and can be applied to the treatment of tumors.

公开(公告)号：US20240336594A1

公开(公告)日：2024-10-10

申请号：US18576708

申请日：2022-06-24

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Bang FU ,  Yinlong LI ,  Wei REN ,  Qichao SHEN ,  Guolong DU ,  Xiaojun ZHOU ,  Yun SUN ,  Yuzhen ZHOU ,  Xiao SUN ,  Weidong CAI ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

CPC classification number: C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

Abstract: A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.

公开(公告)号：US20240174681A1

公开(公告)日：2024-05-30

申请号：US17907117

申请日：2021-03-26

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Jinheng GAO ,  Xiaofeng XU ,  Liang CHEN ,  Zhongxin SUN ,  Yun ZHANG ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/14 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/14 ,  A61K31/519 ,  A61P35/00

Abstract: The present invention relates to a crystalline form and/or maleate, phosphate, L-tartrate, and adipate of the compound represented by the structural formula I, and various crystalline forms of various salt forms, and preparation methods and applications thereof.

公开(公告)号：US20230219890A1

公开(公告)日：2023-07-13

申请号：US18009362

申请日：2021-06-10

Applicant: Betta Pharmaceuticals Co.,Ltd

Inventor： Rongwen YANG ,  Yun SUN ,  Jian ZHANG ,  Xiangkai LIU ,  Pingping WANG ,  Xuegang YI ,  Teng MA ,  Chuanlong HUANG ,  Hong LAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D209/30 ,  C07D209/10 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D405/04 ,  C07D417/04 ,  C07D209/08 ,  C07D471/04 ,  C07D498/04 ,  C07D487/04

CPC classification number: C07D209/30 ,  C07D209/10 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D405/04 ,  C07D417/04 ,  C07D209/08 ,  C07D471/04 ,  C07D498/04 ,  C07D487/04

Abstract: The present invention relates to a compound as represented by formula (I). The present invention also provides compositions and formulations containing such compounds, and methods for using and preparing such compounds.